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Background: Acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) are associated with
accelerated aggravation of clinical symptoms and deterioration of pulmonary function. The mechanisms by which
exacerbations may contribute to airway remodeling and declined lung function are poorly understood. In this
study, we investigated if AE-COPD are associated with differential expression of matrix metalloproteinases (MMPs)
and their tissue inhibitors (TIMPs) in bronchoalveolar lavage (BAL).
Methods: COPD patients undergoing diagnostic bronchoscopy, with either stable disease (n = 53) or AE-COPD
(n = 44), matched for their demographics and lung function parameters were included in this study. Protein levels
of MMP-2,–9,–12 and of TIMP-1 and -2 in BAL were measured by ELISA. Enzymatic activity of MMP-2 and -9 was
assessed by gelatin zymography.
Results: We observed that MMP-9, TIMP-1 and TIMP-2 were significantly increased in BAL during AE-COPD.
Furthermore, there was a significant negative correlation of MMP-9, TIMP-1 and TIMP-2 with FEV1% predicted and
a significant positive correlation of TIMP-1 and TIMP-2 with RV% predicted in AE-COPD. None of MMPs and TIMPs
correlated with DLCO% predicted, indicating that they are associated with airway remodeling leading to obstruction
rather than emphysema. In AE-COPD the gelatinolytic activity of MMP-2 was increased and furthermore, MMP-9
activation was significantly up-regulated irrespective of lung function, bacterial or viral infections and smoking.
Conclusions: The results of this study indicate that during AE-COPD increased expression of TIMP-1, TIMP-2, and
MMP-9 and activation of MMP-9 may be persistent aggravating factors associated with airway remodeling and
obstruction, suggesting a pathway connecting frequent exacerbations to lung function decline.
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Chronic obstructive pulmonary disease (COPD) is a
chronic inflammatory respiratory condition, charac-
terized by progressive airflow limitation that is not fully
reversible. The accelerated deterioration of pulmonary
function may occur at any stage in the course of the
disease. The associated episodes are called acute exa-
cerbations of COPD (AE-COPD). Frequent AE-COPD
hasten lung function decline affecting quality of life, ex-
ercise capacity and survival in patients with COPD [1].
AE-COPD can be triggered by viral or bacterial infec-
tion of the lower respiratory tract [2, 3] and stimulate
both airway and systemic inflammatory responses [4].
Chronic inflammation in COPD and AE-COPD are
associated with disturbances in the homeostasis of extra-
cellular matrix (ECM) molecules, thereby contributing
to airway remodeling, which is a hallmark of the disease
[5, 6]. In the lung, the ECM is subjected to a daily turn-
over of about 10 %, indicating that subtle changes in
turnover rates accumulate to large changes in total ECM
composition with time.
Matrix metalloproteinases (MMPs) are proteolytic
enzymes that degrade ECM components both under
physiological conditions and in pathological processes.
In healthy lung, MMPs and their physiological tissue
inhibitors (TIMPs) are produced by various cell types and
their actions are essential for many physiological pro-
cesses, such as wound healing and cell trafficking [7, 8].
Apart from digesting components of the ECM, MMPs
modulate the activity of other proteases and cytokines
[9–11]. Deregulation of the balance between MMPs and
TIMPs or inappropriate secretion of MMPs by structural
or inflammatory cells are determinant factors in the
pathophysiology of lung diseases, particularly COPD [12].
MMPs are divided into subclasses according to their
substrate specificity and structural characteristics [13].
MMPs are produced by a range of stromal cells as well
as by neutrophils and alveolar macrophages, which are
the major inflammatory cells implicated in COPD [8,
14]. Previous studies have shown that the levels of
MMPs are elevated in the bronchoalveolar lavage (BAL)
fluid from patients with COPD, as compared to controls
[14, 15] and in the sputum of COPD patients during
exacerbation [16]. However, there are no data available
for the expression of MMPs and TIMPs in BAL during
AE-COPD. Moreover, it is uncertain how MMPs and
TIMPs relate to disease severity and phenotype, such as
airway remodeling and emphysema as assessed by body
plethysmography and diffusion capacity, as well as by
CT-scan.
In the present study, we hypothesized that the expres-
sion and/or activity of MMPs and TIMPs is modified
during acute exacerbation of COPD leading to ECM
remodeling associated to lung function limitation. Totest this hypothesis, we investigated a well-characterized




This is a prospective, single center, observational study,
including 97 COPD patients with stable (n = 53) and
AE-COPD (n = 44) undergoing bronchoscopy at the
Clinic of Respiratory Medicine, University Hospital Basel,
Switzerland. All patients gave their written informed con-
sent to participate in the study, which was performed
according to Helsinki regulation and applied to the GCP
guidelines and was approved by the Institutional Review
Board (EKBB 295/07).
COPD was diagnosed according to the GOLD guide-
lines [17]. Patients were considered stable in the absence
of worsening of respiratory symptoms associated with an
exacerbation for at least 4 weeks before bronchoscopy.
Acute exacerbation of COPD was defined as an event
in the natural course of the disease characterized by a
change in the patient’s baseline dyspnea, cough, and/or
sputum that is beyond normal day-to-day variations, is
acute in onset, and may warrant a change in regular medi-
cation in a patient with underlying COPD [17]. In patients
with AE-COPD, bronchoscopies were performed between
2 and 10 days (mean of 7 days) after the onset of exacerba-
tion. Considering that: (a) more than 50 % of patients of
the AE-COPD group were COPD patients with GOLD
stage III and IV; (b) 80 % of the patients in the AE-COPD
group were hospitalized and (c) patients undergoing bron-
choscopy at exacerbation were the ones with persistent
symptoms, thus justifying the clinical indication for
bronchoscopy, the exacerbations could be considered as
clinically relevant severe exacerbations.
Bronchoscopy and BAL sampling
Bronchoscopies were performed, according to standard
procedures [18]. BAL was performed by three installa-
tions of 50 ml each of a pyrogenic-free, sterile, 0.9 %
NaCl solution over the working channel of the broncho-
scope. Recovered BAL was passed through a gauze swab,
transferred into polypropylene tubes and centrifuged for
10 min at 400xg. The cell-free BAL fluid was stored
at -80 °C. The cell pellet was washed twice with PBS and
counted. Cytospins of about 50,000 cells were prepared
using a cyto-centrifuge and stored at -20 °C.
Cytological analysis of BAL samples including differential
cell count was performed [19, 20]. Microbiological analysis
of BAL samples included appropriate stains, cultures and
PCR for bacteria, mycobacteria, fungi and Pneumocystis
jiroveci [19]. Viral infections were also investigated for
rhinovirus, RSV, HSV type 1 and 2, parainfluenza 1 and 3
and CMV, by PCR, culture or immunofluorescence [19].
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Protein content in BAL fluid was determined with the
standard Bradford assay (Bio-Rad, Glattbrugg, Switzerland)
[21]. The gelatinolytic activity in BAL was determined in
aliquots containing 2 μg of proteins using gelatin zymo-
graphy [21]. Gelatinolytic activity was quantified using
the computer-assisted image analysis program of Kodak
(Eastman Kodak, Rochester, NY).
Activation of latent gelatinases was performed by pre-
incubation with 1 mmol/L 4-aminophenylmercuric acet-
ate (Sigma), dissolved in dimethyl sulfoxide, in 50 mmol/L
Tris-hydrochloric acid, pH 7.3, containing 200 mmol/L
NaCI and 5 mmol/L CaCl2, for 24 h at 37 °C.
Protein levels of MMP-2, MMP-9, MMP-12, TIMP-1
and TIMP-2 in BAL were measured using ELISA systems
(Boster Biological Technology, Wuhan, PRC).
Cytospins of BAL were also analyzed by immunocyto-
chemistry for the expression of MMPs using specific
antibodies for MMP-2 and MMP-9 (Spring Bioscience,
Pleasanton, USA) and for MMP-12, (Bioss). The staining
was performed using the Bond Polymer Refine Detection
kit (Leica Biosystems, Newcastle, UK). Specificity of the
staining was also tested following the same incubation
protocol in the absence of the antibody.
Statistical analysis
For data analysis Statistical Package for Social Sciences
(SPSS®, IBM) version 21.0 was used. To evaluate the re-
lationship among different parameters we used a logistic
multivariate regression model analysis [19].
Power calculation
The sample size of 97 COPD patients was based on the
ability to detect a difference between protein levels of
MMP-9 in the BAL given a projected MMP-9 mean of
10.5 μg/g [1.2 to 21.1] at stable COPD and 17.1 μg/g [9.3
to 48.7] at exacerbated COPD (16). Assuming a standard
deviation of 10 μg/g, a total of 84 patients, 42 in each
group, were needed to detect a difference in MMP-9 levels
between stable and AE-COPD with a power of 85 % using
a two-sided p = 0.05 level test.
Results
Demographic and baseline characteristics of the patients
The cohort represented a homogenous population of ad-
equately treated, elderly patients with a relevant smoking
history, severe obstruction, markedly impairment of the
diffusion capacity, mild hyperinflation, mild to moderate
hypoxemia and significant emphysema.
The most common indication for bronchoscopy among
patients with stable COPD was coin lesions (27 %),
evaluation of bronchoscopical or surgical lung volume
reduction procedures (25 %), infiltrates (16 %) and
hemoptysis (8 %).As shown in Table 1, there were no significant differ-
ences in the age, gender, number of current smokers and
smoking history between patients with stable COPD and
with AE-COPD. Clinical characteristics of patients with
stable COPD and AE-COPD were also similar. There
were no significant differences in the stage of the disease
or other clinical parameters such as FEV1 % predicted,
FEV1/VCmax, TLC % predicted, RV % predicted, RV/
TLC % predicted, DLCO % predicted, paO2, paCO2 and
HbCO % between the two groups of patients.
Medication including short-acting β2-agonists alone or
in combination with long-acting muscarinic antagonists
(LAMA), long-acting β2-agonists alone or in combination
with inhaled corticosteroids (ICS), ICS alone, oral cortico-
steroids and xanthines was also similar between stable
COPD and AE-COPD patients. However, significantly
more AE-COPD patients received LAMA (p = 0.043) and
mucolytics (p = 0.035) than stable COPD patients.
Microbiology and cytology of BAL
Microbiological analysis of BAL samples revealed poten-
tial pathogenic bacteria in 43 cases (41.5 % in stable vs.
47.7 % in exacerbation, p-value = 0.404) (Table 2). In
contrast to bacterial, viral detection was more common
among patients with an acute exacerbation (n = 17, 9.4 %
in stable vs 27.3 % in exacerbation, p-value = 0.041.)
Most common viruses encountered were cytomegalo-
virus and respiratory syncytial virus, reflecting the sever-
ity of the disease and the common use of inhaled/oral
steroids. One patient with stable COPD and 4 patients
with AE-COPD had both bacterial and viral detection in
the BAL. Aspergillus colonization was evidenced in 16
cases (13.2 % in stable vs 20.4 % in exacerbation).
Semi-quantitative differential cell counts evidenced a
pleocytosis in 44 of the cases. Additionally, quantitative
differential cell count was possible in 31 samples of the
stable COPD group and in 22 samples of the AE-COPD
group. The percentage of macrophages, neutrophils,
lymphocytes and eosinophils was not significantly differ-
ent between stable COPD and AE-COPD (Table 3).
MMPs and TIMPS are differentially expressed in the BAL
of patients with AE-COPD
MMP-9, TIMP-1 and TIMP-2 were significantly increased
in AE-COPD (Fig. 1a–e, Table 4). However, there were no
significant differences in the molar ratios of MMP-2/
TIMP-2 and MMP-9/TIMP-1 between AE-COPD and
stable COPD.
Bacterial or viral infections were not associated with
significant changes in the levels of MMPs and TIMPs
in the BAL of patients with stable or with AE-COPD
(Additional files 1, 2, 3 and 4).
Gelatin zymography analysis revealed several bands
of gelatinolytic activity (Fig. 2a). The 200 kDa band






Age, years (range) 67.9 (48-81) 69.5 (46-86) 0.402
Gender, males % 60.3 56.8 0.723
Current smokers, n (%) 15 (28.3) 13 (29.5) 0.471
Smoking history (Pack-years), mean (SD) 53.10 (23.83) 48.87 (34.1) 0.080
Severity of COPD – GOLD Stage 0.109
I (FEV1≥ 80 % predicted), n 6 2
II (50 % predicted≤ FEV1≤ 80 % predicted), n 20 14
III (30 % predicted≤ FEV1≤ 50 % predicted), n 14 21
IV (FEV1≤ 30 % predicted), n 13 6
VC % predicted (SD) 89.6 (21.4) 87.7 (17.8) 0.658
FEV1 % predicted (SD) 50.3 (21.5) 48.0 (15.9) 0.543
FEV1/VCmax (SD) 43.3 (13.7) 43.8 (13.7) 0.846
TLC % predicted (SD) 114.7 (22.3) 111.9 (20.0) 0.721
RV % predicted (SD) 162.8 (61.5) 157.6 (45.1) 0.290
DLCO % predicted (SD) 48.3 (19.2) 45.7 (18.3) 0.507
RV/TLC (SD) 0.55 (0.11) 0.56 (0.09) 0.988
paO2, kPa (SD) 8.8 (1.5) 9.2 (1.5) 0.294
paCO2, kPa (SD) 5.3 (0.8) 5.2 (0.8) 0.399
HbCO % (SD) 2.6 (2.5) 2.2 (2.1) 0.414
CT scan assessment, n 29 32
Bronchiectasis 4 7
Moderate emphysema 9 10
Severe emphysema 17 17
COPD-medication, n (%)
SABA 11 (21) 10 (23) 0.768
LABA 7 (13) 5 (11) 0.816
LAMA 8 (15) 14 (32) 0.043
SABA + LAMA 10 (19) 12 (28) 0.295
LABA + ICS 37 (70) 28 (65) 0.625
ICS 3 (6) 5 (12) 0.460
oral corticosteroids 18 (34) 19 (44) 0.306
Xanthines 2 (4) 1 (2) 1.000
Mucolytics 5 (9) 11 (26) 0.035
LTOT 11 (21) 12 (28) 0.414
n number of patients, SD standard deviation, FEV1 forced expiratory volume in one second, RV residual volume, DLCO diffusion capacity of the lung for carbon
monoxide, TLC transfer factor of the lung for carbon monoxide, VC vital capacity, SABA short-acting β2-agonists, LABA long-acting β2-agonists, LAMA long-acting
muscarinic antagonists, ICS inhaled corticosteroids, LTOT long term oxygen therapy
Papakonstantinou et al. Respiratory Research  (2015) 16:78 Page 4 of 12corresponds to multimers of latent MMP-9. The band
of 130 kDa corresponds to MMP-9 in complex with
lipocalin (NGAL), indicating that neutrophils are a
significant source of MMP-9. The bands of 92 kDa and
83 kDa correspond to latent MMP-9 and activated
MMP-9, respectively. The band of 64 kDa corresponds
to latent MMP-2. The identity of these bands wasalso confirmed after treatment of BAL samples with
4-aminophenylmercuric acetate, which activates MMPs
(data not shown).
Quantitative analysis of the lysis bands revealed that
there were no significant differences in the gelatinolytic
activity of latent MMP-9 and activated MMP-9 in BAL
between patients with stable COPD and AE-COPD





Bacteriology positive 22 (41.5) 21 (47.7)
n (% of patients)
Gram staining
Gram positive cocci 14 (26.4) 13 (29.5)
Gram positive rods 9 (17.0) 4 (9.1)
Gram negative rods 6 (11.3) 7 (15.9)
Culture
Streptococcus pneumonia 4 (7.5) -
Streptococcus pyogenes - 2 (4.5)
Moraxella catarrhalis - 1 (2.3)
Staphylococcus aureus - 2 (4.5)
Haemophilus influenza 2 (3.8) -
Enterobacteriace 4 (7.5) 3 (6.8)
Enterococci - 1 (2.3)
Escherichia coli 1(1.9) 2 (4.5)
Pseudomonas aeruginosa - 2 (4.5)
Klebsiella pneumoniae - 1 (2.3)
Virology positive
n (% of patients) 5 (9.4) 12 (27.3)
Rhinovirus 1 (1.9) -
RSV - 4 (9.1)
HSV type 1 1 (1.9) 2 (4.5)
HSV type 2 - 1 (2.3)
parainfluenza 1 1 (1.9) -
parainfluenza 3 1 (1.9) -
CMV 1 (1.9) 5 (11.4)
Bacteriology and virology positive 1 (1.9) 4 (9.1)
Fungi
n (% of patients) 16 (30.2) 23 (52.3)
Aspergillus 7 (13.2) 9 (20.4)
Candida albicans 6 (11.3) 8 (18.1)
Other 3 (5.7) 6 (13.6)
AE-COPD acute exacerbations of COPD, RSV respiratory syncytial virus, HSV
herpes simpex virus, CMV cytomegalovirus, n = number of patients
Table 3 Cytological analysis of BAL samples
Cell type Stable COPD AE-COPD p value
Quantitative differential cell count n = 31 n = 22
% of total cells ± SEM
macrophages 68.69 ± 5.44 57.72 ± 6.75 0.357
neutrophils 26.50 ± 5.58 33.84 ± 6.98 0.582
lymphocytes 5.08 ± 0.67 6.08 ± 1.16 0.828
eosinophils 0.26 ± 0.09 2.20 ± 1.05 0.095
AE-COPD acute exacerbations of COPD, n number of patients, SEM standard
error of the mean
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MMP-2 was significantly increased in the BAL of
AE-COPD patients (Fig. 2b). Furthermore, the ratio of
activated MMP-9/latent MMP-9 was significant higher
in AE-COPD, indicating increased activation of MMP-9
in AE-COPD (Fig. 2c). Overall, the incidence of latent
MMP-9 and activated MMP-9 forms was similar in
stable and exacerbated COPD (43.4 % in stable vs 42.9 %
in exacerbated, p-value = 0.958). However, there was a
significantly higher activation of MMP-9 at exacerbation,
as compared to the stable state (p-value = 0.024).
Cell expression of MMPs
Immunocytochemistry of BAL cells showed that macro-
phages and neutrophils stained positively for MMP-2
(Fig. 3a–b) and MMP-9 (Fig. 3c–d), respectively. How-
ever, only macrophages but not neutrophils stained
positively for MMP-12 (Fig. 3e–f ). The same staining
pattern was observed in BAL cells from either stable
COPD or AE-COPD patients.
Spearman’s correlation analysis
We further investigated the correlation of MMPs and
TIMPs with FEV1%. We observed a significant negative
correlation of MMP-9 with FEV1% in the group of
AE-COPD but not in the stable COPD group (Table 5,
Additional file 5, C-D). Similar results were also ob-
tained when we performed correlation analysis with
FEV/FVC (Table 5). There was no correlation between
MMP-9 with RV% predicted or DLCO% predicted in
neither group, indicating that MMP-9 correlate with
airway tissue remodeling leading to airway obstruction
rather than to emphysema. MMP-2, MMP-9, MMP-12,
TIMP-1 and TIMP-2 did not correlate with the age of
the patients or their smoking history (Table 5).
We also observed a significant negative correlation
between TIMP-1 and TIMP-2 with FEV1% predicted
only in the AE-COPD group (Table 5, Additional file 5,
G–J), indicating that both TIMPs are associated with
airway obstruction in COPD. Furthermore, both TIMPs
were positively correlated with RV% predicted in the
AE-COPD group, indicating that both TIMPs are associ-
ated with emphysematous parenchymal destruction in
AE-COPD (Table 5, Additional file 6, G–J).
Logistic multivariate regression model
In order to balance stable and AE-COPD group con-
cerning several influencing covariates, a one to one pro-
pensity score matching was performed. It was possible
to find 35 matching subjects (Table 6).
Additionally a logistic regression predicting exacerbation
from the ratio of activated MMP-9/latent MMP-9 was
performed with the matched dataset. This ensures that the
prediction is balanced conditional on the matching. The
Fig. 1 Concentration of MMPs and TIMPs in BAL of COPD patients. MMPs and TIMPs were measured in aliquots of BAL from COPD patients at a
stable state and during acute exacerbations (AE-COPD) by ELISA. Figures depict representative distribution of the values between different patients.
The mean and median values, the standard error of the mean and the standard deviation of these measurements are shown in Table 4
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cates the activation of MMP-9 (functional enzyme), was
significantly associated with AE-COPD and this associ-
ation was independent from demographic characteris-
tics of the patients, smoking status, lung function and
infections (Table 7).
Discussion
In this well-characterized cohort, including well-
matched stable and exacerbated patients with COPD,we demonstrated for the first time significant
alterations in ECM proteins during acute exacerbation,
as compared to the stable state in BAL. We have
found a significant increase of MMP-9, TIMP-1 and
TIMP-2 protein levels at exacerbation. While MMP-9,
TIMP-1 and TIMP-2 were negatively associated with
FEV1% predicted, TIMP-1 and TIMP-2 were positively
associated with residual volume. Therefore, MMP-9
and TIMPs seem to be associated with airway obstruc-
tion while TIMPs are potentially related to tissue
Table 4 Descriptive statistics for the concentration of MMPs and TIMPs in BAL of COPD patients
Parameter COPDstatus Mean SEM SDEV Median Min Max p value
MMP-2 (ng/ml BAL) AE 4.34 1.41 8.68 1.16 0.01 48.44 0.055
stable 3.25 2.06 13.50 0.36 0.01 88.33
MMP-9 (ng/ml BAL) AE 670.13 193.04 1,189.97 206.55 0.01 6,158.33 0.012
stable 284.51 74.49 488.48 88.59 0.80 2,331.00
MMP-12 (ng/ml BAL) AE 209.44 56.39 347.64 79.37 0.52 1,415.38 0.114
stable 111.73 28.39 186.17 44.53 2.57 910.00
TIMP-1 (ng/ml BAL) AE 86.77 19.21 118.43 35.66 0.01 476.25 0.028
stable 49.23 9.59 62.88 25.00 0.01 246.15
TIMP-2 (ng/ml BAL) AE 22.69 6.60 40.70 5.47 0.01 206.04 0.030
stable 6.23 1.33 8.71 2.67 0.01 43.64
MMP-2/TIMP-2 (molar ratio) AE 0.85 0.38 2.37 0.078 0.00 12.90 0.791
stable 2.66 2.05 13.43 0.081 0.00 88.32
MMP-9/TIMP-1 (molar ratio) AE 12.01 2.84 17.49 5.18 0.00 71.48 0.284
stable 13.88 4.09 26.81 4.45 0.06 135.30
AE acute exacerbation, SEM standard error of the mean, SDEV standard deviation, Min lower value, Max higher value, MMP matrix metalloproteinase, TIMP tissue
inhibitor of MMP
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9 is markedly activated at AE-COPD, as compared to
the stable state, and this activation is independent of
clinical characteristics including age, gender, cigarette
consumption, severity of obstruction and emphysemaFig. 2 Gelatin zymography analysis. a Representative gelatin zymography o
patients with stable COPD. Bands of enzymatic activity were visualized by n
b Quantitative analysis of gelatinase activity from zymograms using a comp
zymograms from BAL samples obtained from 54 patients with stable COPD anas well as infectious agents at exacerbation. Taken
together, these findings suggest that MMP-9 and
TIMPs may play a significant role in airway remodel-
ing and subsequent lung function decline following
AE-COPD.f BAL aliquots (2 μg of protein) from 4 patients with AE-COPD and 4
egative staining with standard Coomassie brilliant blue dye solution.
uter-supported image analysis program. Values are mean ± SEM of
d 43 patients with AE-COPD. c Ratio of activated MMP-9 to latent MMP-9
Fig. 3 Immunocytochemistry. Immunocytochemical detection of MMP-2, MMP-9 and MMP-12 protein expression on cytospins of BAL from
patients with COPD (magnification 200x). MMP-2 and MMP-9 expression was observed in neutrophils and macrophages (a-d). MMP-12 expression
was only observed in macrophages (e) and not in neutrophils (f). Insert bars represent 50 μm
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pression of MMP-9 in bronchiectatic airways in vivo
[22] and that MMP-9 levels are increased in exhaled
breath condensate in children with bronchiectasis [23].
In our study, we included 4 patients with stable COPD
and 7 patients with AE-COPD that were also diagnosed
with bronchiectasis. In order to investigate if inclusion
of these patients may affect our results, we repeated
measurements of MMP-9 following exclusion of patients
with bronchiectasis from both groups. We obtained very
similar results since we found that MMP-9 was signifi-
cantly increased in the BAL of AE-COPD patients as
compared to stable COPD (p = 0.027), indicating inclu-
sion of this small number of patients with bronchiectasis
in both groups did not influence our results.
Furthermore, we investigated if treatment of COPD
patients with oral steroids may affect the levels of MMP-
9 in BAL. We found that there was a significant increase
(p = 0.019) in the levels of MMP-9 in COPD patients
that received oral steroids (483 ng/ml ± 108), as com-
pared to COPD patients that did not receive oral ste-
roids (402 ng/ml ± 132). These results were expected
since COPD patients that receive oral steroids are
patients with more severe disease and there is a signifi-
cant negative correlation of MMP-9 with FEV1% pre-
dicted, reflecting disease severity. Nevertheless, since thenumber of patients that received oral steroids is the
same in the group of stable COPD and in the group of
AE-COPD we believe that the use of oral steroids did
not influence the results and conclusions of our study.
Previous data suggest that bacterial infections could
induce the expression [24] or the activity [25] of MMPs.
However, in the current study, neither bacterial nor viral
infections were associated with significant changes in
the levels of MMPs and TIMPs in BAL, indicating that
the observed increase of MMP-9, TIMP-1 and TIMP-2
in BAL during AE-COPD resulted from increased secre-
tion by lung resident cell types or by inflammatory cells
such as macrophages and neutrophils invading the lung
during AE-COPD. Interestingly, the number of macro-
phages and neutrophils, which are the main cell types
producing MMPs and TIMPs, were similar in both groups
of patients. Therefore, it is tempting to hypothesize
that the observed differences in MMPs and TIMPs in
AE-COPD resulted either from a different cell source,
such as alveolar type II cells, bronchial epithelial cells,
Clara cells, fibroblasts or smooth muscle cells, or from
induced secretion of MMPs and TIMPs by macrophages
and neutrophils during AE-COPD.
It has been shown that MMP-9 and TIMP-1 levels are
increased in exhaled breath condensate of AE-COPD
patients [26] and that MMP-9 levels are increased in
Table 5 Correlation analysis of protein levels in BAL of MMPs
and TIMPs (Spearman’s rho)
Stable COPD n = 53 AE-COPD n = 44
rho p value rho p value
Age of patients
MMP-2 -0.162 0.266 -0.113 0.482
MMP-9 0.090 0.527 0.001 0.931
MMP-12 0.072 0.616 -0.055 0.726
TIMP-1 -0.021 0.884 -0.067 0.675
TIMP-2 0.015 0.922 -0.141 0.379
Packs per year
MMP-2 -0.102 0.499 0.126 0.452
MMP-9 -0.236 0.103 -0.042 0.802
MMP-12 -0.149 0.317 -0.033 0.839
TIMP-1 -0.069 0.636 0.012 0.940
TIMP-2 -0.088 0.578 -0.101 0.547
FEV1 % predicted
MMP-2 -0.140 0.339 -0.186 0.251
MMP-9 -0.241 0.085 -0.475a 0.002
MMP-12 -0.242 0.087 -0.281 0.071
TIMP-1 -0.162 0.246 -0.510a 0.001
TIMP-2 -0.166 0.281 -0.492a 0.001
FEV/FVC
MMP-2 -0.049 0.741 -0.130 0.424
MMP-9 -0.151 0.284 -0.364b 0.019
MMP-12 -0.107 0.457 -0.180 0.254
TIMP-1 -0.114 0.418 -0.420a 0.006
TIMP-2 -0.177 0.250 -0.365b 0.020
RV % predicted
MMP-2 -0.113 0.445 0.175 0.287
MMP-9 0.106 0.459 0.307 0.054
MMP-12 0.042 0.773 0.099 0.537
TIMP-1 0.135 0.339 0.365b 0.021
TIMP-2 0.161 0.302 0.344b 0.032
DLCO % predicted
MMP-2 -0.109 0.475 0.097 0.566
MMP-9 -0.057 0.700 0.079 0.636
MMP-12 -0.026 0.860 0.058 0.725
TIMP-1 -0.016 0.911 -0.125 0.454
TIMP-2 -0.199 0.219 0.069 0.684
AE acute exacerbation, MMP matrix metalloproteinase, TIMP tissue inhibitor
of MMP
aCorrelation is significant at the 0.01 level (2-tailed)
bCorrelation is significant at the 0.05 level (2-tailed)
Table 6 Propensity score matching
Variable Stable COPD n = 35 AE-COPD n = 35 P-Value
Age 69.2 (6.44) 69.5 (9.80) 0.863
Sex 0.37 (0.49) 0.43 (0.50) 0.632
Packs per year 50.6 (23.1) 47.9 (36.1) 0.715
FEV1 % predicted 50.7 (21.6) 48.6 (16.3) 0.653
RV % predicted 153 (46.5) 160 (45.9) 0.527
DLCO % predicted 46.8 (19.8) 46.2 (16.7) 0.885
Bacteriology 1.000
negative 19 (54.3 %) 19 (54.3 %)
positive 16 (45.7 %) 16 (45.7 %)
Virology 0.511
negative 31 (88.6 %) 28 (80.0 %)
positive 4 (11.4 %) 7 (20.0 %)
activation of MMPa 1.28 (0.97) 0.56 (0.56) 0.018
AE acute exacerbation, FEV1 forced expiratory volume in one second, RV
residual volume, DLCO diffusion capacity of the lung for carbon monoxide
aExpressed as the ratio of proMMP-9/MMP-9
Table 7 Logistic, multivariate regression model for the prediction
of AE-COPD among the study population
Variable OR 95 %-CI p value
activation of MMP-9 0.159 (0.031-0.816) 0.028
Age 1.064 (0.958-1.181) 0.244
Sex 2.535 (0.189-33.935) 0.482
Packs per year 0.978 (0.935-1.022) 0.320
FEV1 % predicted 1.027 (0.947-1.115) 0.513
RV % predicted 1.003 (0.974-1.033) 0.859
DLCO % predicted 0.952 (0.870-1.042) 0.286
Bacteriology 0.361 (0.043-3.055) 0.350
Virology 0.264 (0.014-4.919) 0.372
AE acute exacerbation, FEV1 forced expiratory volume in one second, RV
residual volume, DLCO diffusion capacity of the lung for carbon monoxide
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showed that TIMP-1, as well as TIMP-2 levels were sig-
nificantly increased in BAL during AE-COPD and that
the molar ratios of MMP-9/TIMP-1 and MMP-2/TIMP-2 were not altered significantly. TIMPs bind to MMPs in
1:1 molar ratio to inhibit their activity. However, MMPs
do not only act as secreted enzymes, but they also bind
to cell surface where they exert elastolytic activity. Ap-
proximately 80 % of MMP-9, synthesized by neutrophils,
remains associated with the surface of the cells and is
not neutralized by TIMPs [27]. Furthermore, in different
parts of the microenvironment of the airways, MMPs or
TIMPs may predominate and therefore, the increased
levels of TIMPs in BAL during AE-COPD may not ne-
cessarily result in inhibition of MMP-9 activity.
MMP-2 activity was also increased in BAL during AE-
COPD, which is in good agreement with previous stud-
ies showing that there is increased immune-reactivity for
MMP-2 in the lungs of patients with COPD, mainly in
alveolar macrophages and airway epithelial cells [28] and
Papakonstantinou et al. Respiratory Research  (2015) 16:78 Page 10 of 12that there is increased expression and activity of MMP-2
in the lungs and sputum of patients with COPD [29].
Despite the available literature on the role of MMPs
and TIMPs in COPD, the information regarding the in-
volvement of these molecules in AE-COPD remains elu-
sive. In our study, we report that there is a significant
increase in the concentration of MMP-9 in BAL during
AE-COPD and moreover, a significant activation of the
enzyme, independent of age, sex, smoking status, lung
function parameters and microbiology. These results in-
dicate that activation of MMP-9 is a parameter directly
associated with AE-COPD irrespective of demographic
or clinical characteristics of the COPD patients.
It has been shown that in patients with emphysema,
there is elevated concentration of MMP-1 and MMP-9
in BAL and increased expression of these MMPs in mac-
rophages [8]. Alveolar macrophages from healthy
smokers express more MMP-9 than those from healthy
non-smokers [30] and MMP-9 expression is increased in
cells from patients with COPD [31], with enhanced elas-
tolytic activity [32]. MMP-9 and the ratio of MMP-9 to
TIMP-1 are increased in induced sputum of patients
with COPD [33]. MMP-9 activity is increased in the lung
parenchyma of patients with emphysema [34], and cor-
related with FEV1 [35]. Here, we observed a significant
negative correlation of MMP-9, TIMP-1 and TIMP-2
with FEV1% predicted and of TIMP-1 and TIMP-2 with
RV% predicted in the AE-COPD group. The fact that
none of the investigated molecules correlated with
DLCO% predicted indicates that they are associated with
tissue remodeling leading to airway obstruction but not
to emphysema.
It remains to be elucidated if the observed alterations
in the levels and/or activity of MMPs and TIMPs that
we observe in the present study are causative for AE-
COPD or a consequence of the disease. Since bacterial
and viral infections, which are the main causative factors
for AE-COPD, were not associated with significant
changes in the levels of MMPs and TIMPs in BAL, it is
more likely that deregulation of these molecules are in-
dependent causative factors for AE-COPD. As MMPs
and TIMPs might be casually involved in the develop-
ment of an exacerbation, targeting TIMPs or gelatinases
with specific and non toxic agents, such as the third
generation of highly selective MMP inhibitors [36] or
monoclonal antibodies against MMPs [37] may offer
valuable treatments to confront airway remodeling asso-
ciated with AE-COPD.
Increasing evidence suggest that MMP-12, plays a role
in lung destruction in COPD. Data obtained from a large
multiple cohort association study, linked the variation
of MMP-12 with lung function in smokers and the risk
of developing COPD [38], while, in animal models of
COPD, the deletion of MMP-12 in mice exposed tocigarette smoke protects these animals from emphysema
[39]. Patients with COPD have elevated levels of MMP-
12 in their airways and increased numbers of MMP-12
expressing macrophages [40]. In our study, MMP-12
was increased in AE-COPD, as compared to stable
COPD. However, this result was not statistically signifi-
cant. Furthermore, in our cohort of AE-COPD patients
we did not observe any statistically significant correl-
ation of MMP-12 with smoking status, FEV1% predicted,
RV% predicted, or DLCO% predicted.
Our study has a few limitations. It is a single center
study that included adequate patients requiring diagnos-
tic bronchoscopy. The time lapse between the onset of
AE-COPD and bronchoscopy varied between patients
from 2–10 days (mean of 7 days). However, when we
stratified the measurements for MMP-2, MMP-9, MMP-
12, TIMP-1 and TIMP-2 in BAL by the time lapse from
the onset of the exacerbation (1–3, 4–6 and 7–10 days),
we did not observe significant differences in the values
of central tendency for any of the parameters measured.
Taking into account the results of the stratified analyses,
as well as the fact that patients undergoing bronchos-
copy were the ones with persistent symptoms, we care-
fully assume that the time lapse between the onset of
exacerbation and the collection of the BAL at bron-
choscopy does not preclude our interpretations on the
association between MMPs and TIMPs in BAL and
exacerbations.
Another limitation is that we were unable to evaluate
the same patient both at exacerbation and at stable state.
However, this must be regarded as an almost obligatory
limitation, since it would be extremely scarce to find pa-
tients that would require diagnostic bronchoscopy both
at exacerbation and at stable state within a short time
interval. At the same time, it would be unethical to per-
form, for the shake of proper research methodology, a
second BAL at a patient at exacerbation, who recently
underwent BAL at stable state for diagnostic reasons. To
compensate this, we have analyzed almost 100 BAL sam-
ples of patients with either exacerbated or stable disease.
Difficulties in performing BAL at exacerbation are well
described and might explain the scarcity of data in this
setting. A further aspect to consider is that the sample
size provided the study sufficient power to detect clinical
relevant differences between both conditions. Although
the analysis of non-paired data tends to produce larger
deviations from the measures of central tendency, co-
horts at stable and exacerbated condition were very well
balanced. This was confirmed by the endorsing results
of the multivariate analysis and the propensity score.
Therefore, we believe it is fair to assume that the re-
ported differences in the expression and/or activity of
MMPs and TIMPs were rather related to the manifest-
ation of the exacerbations per se. A further strength is
Papakonstantinou et al. Respiratory Research  (2015) 16:78 Page 11 of 12the fact that we could associate protein and activity
values to an extensive clinical characterization, including
body plethysmography results, detailed microbiology ana-
lysis and CT-scan findings.Conclusions
The data presented in this study indicate that during
AE-COPD increased expression of TIMP-1, TIMP-2,
and MMP-9 and activation of MMP-9 may be
persistent aggravating factors associated with airway
remodeling and obstruction, suggesting a pathway con-
necting frequent exacerbations to lung function de-
cline. MMP-9 and TIMPs could potentially represent
valuable therapeutic targets to counteract remodeling
and parenchymal destruction associated with recurrent
exacerbations.Additional files
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